Abstract:Silencing the inhibitor of apoptosis (IAP) by RNAi is a promising method for tumor therapy. One of the major challenges lies in how to sequentially overcome the system barriers in the course of the tumor targeting delivery, especially in the tumor accumulation and penetration. Herein we developed a novel stimuli-responsive polysaccharide enveloped liposome carrier, which was constructed by layer-by-layer depositing redox-sensitive amphiphilic chitosan (CS) and hyaluronic acid (HA) onto the liposome and then loading IAP inhibitor survivin-shRNA gene and permeation promoter hyaluronidase (HAase) sequentially. The as-prepared HA/HAase/CS/liposome/shRNA (HCLR) nanocarrier was verified to be stable in blood circulation due to the negative charged HA shield. The tumor targeting recognition and the enhanced tumor accumulation of HCLR were visualized by fluorescence resonance energy transfer (FRET) and in vivo fluorescence biodistribution. The deshielding of HA and the protonizing of CS in slightly acidic tumor extracellular pH environment (pHe, 6.8–6.5) were demonstrated by ζ potential change from −23.1 to 29.9 mV. The pHe-responsive HAase release was confirmed in the tumor extracellular mimicking environments, and the intratumoral biodistribution showed that the tumor penetration of HCLR was improved. The cell uptake of HCLR in pHe environment was significantly enhanced compared with that in physiological pH environment. The increased shRNA release of HCLR was approved in 10 mM glutathione (GSH) and tumor cells. Surprisingly, HCLR suppressed the tumor growth markedly through survivin silencing and meanwhile maintained low toxicity to mice. This study indicates that the novel polysaccharide enveloped HCLR is promising in clinical translation, thanks to the stimuli-triggered tumor accumulation, tumor penetration, cell uptake, and intracellular gene release.

Delivery of Survivin Sirna Using Cationic Diphenylalanine Vesicles

Efficient Delivery of Notch1 Sirna to Skov3 Cells by Cationic Cholesterol Derivative-Based Liposome

Synergistic Treatment of Ovarian Cancer by Co-Delivery of Survivin Shrna and Paclitaxel Via Supramolecular Micellar Assembly

Magnetic Cationic Amylose Nanoparticles Used to Deliver Survivin-Small Interfering RNA for Gene Therapy of Hepatocellular Carcinoma In Vitro

Highly Stable Polyglutamate Derivatives/sirna Polyplex Efficiently Down-Relegate Survivin Expression and Augment the Efficacy of Cisplatin.

A biocompatible glycogen based nanoparticle coating with lipid bilayer for intracellular delivery of survivin siRNA to HeLa cells

Stimuli-Responsive Polysaccharide Enveloped Liposome for Targeting and Penetrating Delivery of survivin-shRNA into Breast Tumor

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

Inhibitory Effect of Survivin Antisense Oligodeoxynucleotides on HepG2 Cells by Using Polyamidoamine Dendrimer As Gene Delivery System

Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin

Co-delivery of gambogenic acid and VEGF-siRNA with anionic liposome and polyethylenimine complexes to HepG2 cells

Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.

Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery

VEGF Sirna Delivered by Polycation Liposome-Encapsulated Calcium Phosphate Nanoparticles for Tumor Angiogenesis Inhibition in Breast Cancer

The Ph-Triggered Triblock Nanocarrier Enabled Highly Efficient Sirna Delivery for Cancer Therapy

Efficient Systemic Delivery Of Sirna By Using High-Density Lipoprotein-Mimicking Peptide Lipid Nanoparticles

Nucleolin-targeted cationic nanoparticle for delivery of survivin shRNA against colorectal cancer in vitro and in vivo

Pegylated Carboxymethyl Chitosan/Calcium Phosphate Hybrid Anionic Nanoparticles Mediated Htert Sirna Delivery for Anticancer Therapy

Co-Delivery of Doxorubicin and Survivin Shrna-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

In Vitro Investigation of RGD-modified Stabilized Cationic Liposomes As Non-Viral Vehicle for Sirna Delivery

Magnetically guided survivin-siRNA delivery and simultaneous dual-modal imaging visualization based on Fe3O4@mTiO2 nanospheres for breast cancer.